Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$8.33 USD
-0.15 (-1.77%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $8.34 +0.01 (0.12%) 5:36 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Amicus Therapeutics, Inc. has a market cap of $2.61B, which represents its share price of $8.48 multiplied by its outstanding shares number of 308.24M. As a mid-cap company, FOLD's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
FOLD 8.33 -0.15(-1.77%)
Will FOLD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
Other News for FOLD
Interesting FOLD Put And Call Options For November 21st
Pocket Pivot appears for FOLD after 6.4% move
Amicus Therapeutics (FOLD) Upgraded by Needham with Increasing Sales Potential
Amicus upgraded to Buy at Needham banking on kidney disease therapy
Target initiated, Nike upgraded: Wall Street’s top analyst calls